{
  "context": {
    "rules": [
      "Rule1: Either a person approves a drug or the drug is a generic drug.",
      "Rule2: If an agency monitors a financial firm, then whenever that firm violates a regulation with a financial product, it does not face a fine for that product.",
      "Rule3: Provided that an agency investigates a financial firm, it also audits that firm.",
      "Rule4: Should a financial product be high risk, it requires licensing.",
      "Rule5: Given that a financial product is high risk, it has leverage limits.",
      "Rule6: A financial product is either high risk or medium risk.",
      "Rule7: Assuming a financial product is medium risk, then provided that the drug is not approved for sale and not a generic drug, the drug is for restricted use.",
      "Rule8: If a financial product requires disclosure, then in the event that the drug is not approved for sale and not a generic drug, the drug is for restricted use.",
      "Rule9: Provided that a financial product requires licensing, it also requires disclosure.",
      "Rule10: Whenever an agency has conflicting policy, it supports the industry.",
      "Rule11: In case an agency has conflicting policy, it does not support the industry.",
      "Rule12: Either an agency has conflicting policy, or if a legislator proposes legislation for a financial product, then whenever the agency does not investigate that product, and it finds the product risky, the agency issues a warning for the product.",
      "Rule13: An agency either investigates a financial product or bans that product.",
      "Rule14: If a legislator drafts a bill for a financial product, then that legislator sponsors the bill for the product.",
      "Rule15: Provided that a legislator sponsors a bill for a financial product, then in case the agency does not investigate that product, and it finds the product risky, the agency issues a warning for the product.",
      "Rule16: Either a financial product is a safe investment or a person does not approve a drug.",
      "Rule17: If a financial product is an approved fund, then it is a regulated investment.",
      "Rule18: Provided that a financial product is a restricted fund, it is not a safe investment.",
      "Rule19: In case a financial product is an established fund, it is an approved fund.",
      "Rule20: Should a financial product be a new fund, then it is a restricted fund.",
      "Rule21: If a financial product is a domestic fund, then it is an established fund.",
      "Rule22: Provided that an agency bans a financial product, a person does not approve a drug.",
      "Rule23: In case a financial product is a foreign fund, then it is a new fund.",
      "Rule24: If a financial product is an investment product, then it is either a hybrid fund, or a domestic fund, or a foreign fund.",
      "Rule25: Provided that a financial product is under normal market conditions, the agency does not take emergency action on that product.",
      "Rule26: In case a financial product contributes to economic stability, it does not experience a market crash.",
      "Rule27: Should an agency find a financial product risky, then a person does not approve a drug.",
      "Rule28: If a financial product is in a boom period, then it is in a growth period.",
      "Rule29: Whenever an agency conducts an initial review of a financial product, then if it investigates that product, a person does not approve a drug.",
      "Rule30: An agency either conducts an initial review of a financial product or a followup review of that product.",
      "Rule31: Either a financial product is compliant, or if the agency conducts a followup review of the product, then whenever it investigates the product, a person does not approve a drug.",
      "Rule32: In case a financial product has a major violation, then it has a minor violation.",
      "Rule33: A financial product is under pending investigation, or if the product is not noncompliant and not compliant, then it has a major violation.",
      "Rule34: Should a financial firm follow standard compliance for a financial product, then it does not have a regulatory exception for that product.",
      "Rule35: A financial firm either follows standard compliance for a financial product or enhanced compliance for that product.",
      "Rule36: Provided that a financial firm follows enhanced compliance for a financial product, it does not have a regulatory exception for that product.",
      "Rule37: Either a financial firm conducts an internal audit, or if a person submits a whistleblower report about the firm, then the firm does not violate a regulation with a financial product.",
      "Rule38: Provided that a financial firm obtains senior approval for a financial product, then if it undergoes a compliance officer review for the product, and the firm violates a regulation with the product, it takes corrective action for the product.",
      "Rule39: A financial firm either obtains senior approval for a financial product or committee approval for that product.",
      "Rule40: In case a financial firm obtains committee approval for a financial product, then if it undergoes a compliance officer review for the product, and the firm violates a regulation with the product, it takes corrective action for the product.",
      "Rule41: Should a financial firm self-report for a financial product, then it does not face a fine for that product.",
      "Rule42: In case a financial firm makes a mandatory disclosure for a financial product, then it self-reports for that product.",
      "Rule43: If a legislator proposes legislation for a financial product, then that legislator drafts a bill for the product.",
      "Rule44: Provided that a legislator proposes legislation for a financial product, then that legislator amends legislation for the product.",
      "Rule45: If a financial product is complex, then it is structured.",
      "Rule46: A financial product is either complex or simple.",
      "Rule47: Provided that a financial product is simple, then whenever the drug is not approved for sale and not a generic drug, the drug is for restricted use.",
      "Rule48: Should a financial product be structured, then in the event that the drug is not approved for sale and not a generic drug, the drug is for restricted use.",
      "Rule49: If a financial product has capital requirements, then it requires disclosure.",
      "Rule50: Whenever a financial product undergoes risk assessment, then if it has leverage limits, it has capital requirements.",
      "Rule51: In case a financial product undergoes stress testing, then provided that it has leverage limits, it has capital requirements.",
      "Rule52: Should a legislator amend legislation for a financial product, then whenever the agency does not investigate that product, and it finds the product risky, the agency issues a warning for the product.",
      "Rule53: If a financial product has a quarterly review, then it either undergoes risk assessment or stress testing.",
      "Rule54: A financial product either has a quarterly review or an annual review.",
      "Rule55: Provided that a financial product has an annual review, then it either undergoes risk assessment or stress testing.",
      "Rule56: In case a drug receives conditional approval, then it receives full approval.",
      "Rule57: If a drug is in phase 1 trial, then it is either approved for sale or a generic drug.",
      "Rule58: Provided that a drug is in phase 2 trial, then it is either approved for sale or a generic drug.",
      "Rule59: If a drug receives research funding, then whenever it is in clinical research, it is either in phase 1 trial or phase 2 trial.",
      "Rule60: Should a financial firm violate a regulation with a financial product, it makes a voluntary disclosure for that product.",
      "Rule61: If a financial firm violates a regulation with a financial product, then it faces a fine for that product.",
      "Rule62: Either a financial firm violates a regulation with a financial product or a drug is a generic drug.",
      "Rule63: Should the drug not be approved for sale and not be a generic drug, then it is not for restricted use.",
      "Rule64: Provided that it is not the case that if the agency performs a routine inspection on a financial product, then if it investigates that product, it finds the product risky, the agency takes emergency action on that product.",
      "Rule65: Provided that the financial product is not noncompliant and not compliant, it does not have a minor violation.",
      "Rule66: Whenever it is not the case that if a financial firm makes a voluntary disclosure for a financial product, then it makes a mandatory disclosure for that product, the firm has an extended deadline for the product.",
      "Rule67: In case it is not the case that if a financial firm has an extended deadline for a financial product, then it is granted an extension for that product, the firm is denied an extension for the product.",
      "Rule68: Should it not be the case that if a financial firm violates a regulation with a financial product, then it does not face a fine for that product, the firm has a regulatory exception for the product.",
      "Rule69: Should it not be the case that if it is not the case that if the drug is not approved for sale and not a generic drug, then the drug is for restricted use, then the drug receives conditional approval, the drug receives fast-track approval.",
      "Rule70: Provided that it is not the case that if it is not the case that if the drug is not approved for sale and not a generic drug, then the drug is for restricted use, then the drug receives conditional approval, the drug does not receive fast-track approval.",
      "Rule71: In case it is not the case that if the financial product is not under normal market conditions, then it is in a volatile market, the product experiences a market crash.",
      "Rule72: Provided that an agency does not monitor a financial firm, it investigates that firm.",
      "Rule73: Provided that a financial product does not contribute to economic stability, it is in a boom period."
    ],
    "facts": [
      "Fact1: A financial product is an investment product.",
      "Fact2: An agency performs a routine inspection on a financial product.",
      "Fact3: A person submits a whistleblower report about a financial firm.",
      "Fact4: A financial firm undergoes a compliance officer review for a financial product.",
      "Fact5: A legislator proposes legislation for a financial product.",
      "Fact6: A drug is in clinical research.",
      "Fact7: A drug receives research funding.",
      "Fact8: It is not the case that an agency audits a financial firm.",
      "Fact9: It is not the case that a drug is approved for sale.",
      "Fact10: It is not the case that a financial product is a regulated investment.",
      "Fact11: It is not the case that a financial product is a hybrid fund.",
      "Fact12: It is not the case that a financial product is in a volatile market.",
      "Fact13: It is not the case that a financial product is in a growth period.",
      "Fact14: It is not the case that a financial product is noncompliant.",
      "Fact15: It is not the case that a financial product is under pending investigation.",
      "Fact16: It is not the case that an agency issues a warning for a financial product.",
      "Fact17: It is not the case that a financial firm conducts an internal audit.",
      "Fact18: It is not the case that a financial firm takes corrective action for a financial product.",
      "Fact19: It is not the case that a financial firm is granted an extension for a financial product.",
      "Fact20: It is not the case that a financial firm is denied an extension for a financial product.",
      "Fact21: It is not the case that a drug receives full approval."
    ]
  },
  "question": "A drug is a generic drug."
}